A GLP-1 titration schedule lists a starting dose held for a fixed period, usually four weeks, before stepping up to a higher labelled dose: semaglutide starts at 0.25 mg weekly and tirzepatide at 2.5 mg weekly. It is a published fact about the branded product, not a plan for you, and copying one into a compounded vial is not the same thing as following it.
What is a GLP-1 titration schedule?
The US prescribing information for the branded semaglutide products sets out two different ladders. Ozempic starts at 0.25 mg once weekly for four weeks, then 0.5 mg once weekly, with a maximum of 2 mg once weekly. Wegovy steps 0.25, 0.5, 1, 1.7 and 2.4 mg once weekly, four weeks at each step. Both are reproduced, with the label each comes from, on the semaglutide calculator page.
The tirzepatide products start at 2.5 mg once weekly for four weeks, then 5 mg once weekly, with increases in 2.5 mg increments after at least four weeks at the current dose, to a maximum of 15 mg once weekly. Those are on the tirzepatide calculator page with their sources.
Two things about that phrasing matter. The first step has a stated duration. The later steps mostly do not: they say at least four weeks at the current dose before an increase, which is a floor, not a schedule. A table that prints a tidy duration next to every row has invented the tidiness.
Each step is a new arithmetic problem, not a new vial
The concentration of your vial does not change when the dose does. Only the draw changes. From a vial at 10 mg per mL:
- 2.5 mg is 0.25 mL, 25 units on U-100.
- 5 mg is 0.5 mL, 50 units.
- 7.5 mg is 0.75 mL, 75 units.
So a step up is a step up the barrel, and the same vial empties faster. Doses per vial falls with every increase, which is the figure the calculator reports next to the reading, and the reason a vial that lasted a month at the first step does not last a month at the third. The method is the same one in how to convert mg to units.
Half lives explain the four week steps, they do not justify a dose
Semaglutide has a labelled elimination half life of about one week and tirzepatide about five days. A weekly injection of a compound with a half life of that length accumulates for several weeks before levels stop rising, which is the pharmacological reason labels hold each step for weeks rather than days. That is context for reading a label, not a reason to design a schedule. This site publishes no schedule of its own, and for compounds with no approved label it publishes no dose figures at all, as on the retatrutide page.
In short: a titration schedule is a labelled sequence of dose steps, each held for a minimum duration, and reading one correctly means treating it as a published fact about that product, not a plan to copy onto a different vial.